中国医药导报
中國醫藥導報
중국의약도보
China Medical Herald
2015年
30期
124-127
,共4页
康复新液%雷贝拉唑肠溶片%消化性溃疡%临床效果
康複新液%雷貝拉唑腸溶片%消化性潰瘍%臨床效果
강복신액%뢰패랍서장용편%소화성궤양%림상효과
Kangfuxin Liquid%Rabeprazole Sodium Enteric-coated Tablets%Peptic ulcer%Clinical effect
目的：研究康复新液联合雷贝拉唑肠溶片治疗消化性溃疡的临床效果。方法选取2013年4月~2014年12月重庆市江津区中心医院收治的84例消化性溃疡患者作为研究对象，按照入院顺序将所有对象随机分为对照组和观察组，每组各42例。对照组患者给予含雷贝拉唑肠溶片的三联疗法：雷贝拉唑肠溶片口服，20 mg/次，1次/d+阿莫西林胶囊1.0 g/次，2次/d+甲硝唑片0.2 g/次，2次/d。观察组在对照组的基础上给予康复新液口服，10 mL/次，3次/d。4周为1个疗程。观察并比较两组临床症状积分、临床疗效、胃镜疗效、幽门螺杆菌根除情况、溃疡半年内复发情况以及不良反应发生情况。结果治疗1个疗程后，对照组和观察组腹痛、腹胀、泛酸、烧心、嗳气、恶心呕吐六项症状及总积分[对照组：(1.56±0.49)、(0.98±0.22)、(1.05±0.24)、(1.34±0.36)、(0.92±0.14)、(1.04±0.22)、(5.84±1.92)分；观察组(1.22±0.31)、(0.86±0.17)、(0.96±0.19)、(1.27±0.34)、(0.91±0.11)、(1.06±0.27)、(4.44±1.53)分]均较治疗前[对照组：(4.27±1.41)、(3.64±1.31)、(4.63±1.93)、(3.99±1.25)、(3.61±0.98)、(4.13±1.26)、(22.14±5.16)分；观察组：(4.52±1.84)、(3.85±1.21)、(4.71±1.98)、(4.01±1.29)、(3.59±0.95)、(4.25±1.39)、(23.45±5.78)分]显著下降，差异均有统计学意义(P<0.05)。两组治疗后组间比较差异无统计学意义(P>0.05)。观察组临床总有效率(95.24%)明显高于对照组(88.10%)，差异有统计学意义(P<0.05)。观察组胃镜下总有效率达100.00%，显著高于对照组的85.71%，差异有高度统计学意义(P<0.01)。两组幽门螺杆菌根除率比较差异无统计学意义(P>0.05)，观察组溃疡半年内复发率(21.43%)明显低于对照组(33.33%)，差异有统计学意义(P<0.05)。治疗过程中，对照组有3例口干患者。观察组有2例轻微腹泻、1例口干患者，停药后自行缓解。结论康复新液联合雷贝拉唑肠溶片治疗消化性溃疡临床效果显著，能迅速改善临床症状，预防溃疡复发，且不良反应轻微，值得临床进一步推广应用。
目的：研究康複新液聯閤雷貝拉唑腸溶片治療消化性潰瘍的臨床效果。方法選取2013年4月~2014年12月重慶市江津區中心醫院收治的84例消化性潰瘍患者作為研究對象，按照入院順序將所有對象隨機分為對照組和觀察組，每組各42例。對照組患者給予含雷貝拉唑腸溶片的三聯療法：雷貝拉唑腸溶片口服，20 mg/次，1次/d+阿莫西林膠囊1.0 g/次，2次/d+甲硝唑片0.2 g/次，2次/d。觀察組在對照組的基礎上給予康複新液口服，10 mL/次，3次/d。4週為1箇療程。觀察併比較兩組臨床癥狀積分、臨床療效、胃鏡療效、幽門螺桿菌根除情況、潰瘍半年內複髮情況以及不良反應髮生情況。結果治療1箇療程後，對照組和觀察組腹痛、腹脹、汎痠、燒心、噯氣、噁心嘔吐六項癥狀及總積分[對照組：(1.56±0.49)、(0.98±0.22)、(1.05±0.24)、(1.34±0.36)、(0.92±0.14)、(1.04±0.22)、(5.84±1.92)分；觀察組(1.22±0.31)、(0.86±0.17)、(0.96±0.19)、(1.27±0.34)、(0.91±0.11)、(1.06±0.27)、(4.44±1.53)分]均較治療前[對照組：(4.27±1.41)、(3.64±1.31)、(4.63±1.93)、(3.99±1.25)、(3.61±0.98)、(4.13±1.26)、(22.14±5.16)分；觀察組：(4.52±1.84)、(3.85±1.21)、(4.71±1.98)、(4.01±1.29)、(3.59±0.95)、(4.25±1.39)、(23.45±5.78)分]顯著下降，差異均有統計學意義(P<0.05)。兩組治療後組間比較差異無統計學意義(P>0.05)。觀察組臨床總有效率(95.24%)明顯高于對照組(88.10%)，差異有統計學意義(P<0.05)。觀察組胃鏡下總有效率達100.00%，顯著高于對照組的85.71%，差異有高度統計學意義(P<0.01)。兩組幽門螺桿菌根除率比較差異無統計學意義(P>0.05)，觀察組潰瘍半年內複髮率(21.43%)明顯低于對照組(33.33%)，差異有統計學意義(P<0.05)。治療過程中，對照組有3例口榦患者。觀察組有2例輕微腹瀉、1例口榦患者，停藥後自行緩解。結論康複新液聯閤雷貝拉唑腸溶片治療消化性潰瘍臨床效果顯著，能迅速改善臨床癥狀，預防潰瘍複髮，且不良反應輕微，值得臨床進一步推廣應用。
목적：연구강복신액연합뢰패랍서장용편치료소화성궤양적림상효과。방법선취2013년4월~2014년12월중경시강진구중심의원수치적84례소화성궤양환자작위연구대상，안조입원순서장소유대상수궤분위대조조화관찰조，매조각42례。대조조환자급여함뢰패랍서장용편적삼련요법：뢰패랍서장용편구복，20 mg/차，1차/d+아막서림효낭1.0 g/차，2차/d+갑초서편0.2 g/차，2차/d。관찰조재대조조적기출상급여강복신액구복，10 mL/차，3차/d。4주위1개료정。관찰병비교량조림상증상적분、림상료효、위경료효、유문라간균근제정황、궤양반년내복발정황이급불량반응발생정황。결과치료1개료정후，대조조화관찰조복통、복창、범산、소심、애기、악심구토륙항증상급총적분[대조조：(1.56±0.49)、(0.98±0.22)、(1.05±0.24)、(1.34±0.36)、(0.92±0.14)、(1.04±0.22)、(5.84±1.92)분；관찰조(1.22±0.31)、(0.86±0.17)、(0.96±0.19)、(1.27±0.34)、(0.91±0.11)、(1.06±0.27)、(4.44±1.53)분]균교치료전[대조조：(4.27±1.41)、(3.64±1.31)、(4.63±1.93)、(3.99±1.25)、(3.61±0.98)、(4.13±1.26)、(22.14±5.16)분；관찰조：(4.52±1.84)、(3.85±1.21)、(4.71±1.98)、(4.01±1.29)、(3.59±0.95)、(4.25±1.39)、(23.45±5.78)분]현저하강，차이균유통계학의의(P<0.05)。량조치료후조간비교차이무통계학의의(P>0.05)。관찰조림상총유효솔(95.24%)명현고우대조조(88.10%)，차이유통계학의의(P<0.05)。관찰조위경하총유효솔체100.00%，현저고우대조조적85.71%，차이유고도통계학의의(P<0.01)。량조유문라간균근제솔비교차이무통계학의의(P>0.05)，관찰조궤양반년내복발솔(21.43%)명현저우대조조(33.33%)，차이유통계학의의(P<0.05)。치료과정중，대조조유3례구간환자。관찰조유2례경미복사、1례구간환자，정약후자행완해。결론강복신액연합뢰패랍서장용편치료소화성궤양림상효과현저，능신속개선림상증상，예방궤양복발，차불량반응경미，치득림상진일보추엄응용。
Objective To study the clinical effect of Kangfuxin Liquid combined with Rabeprazole Sodium Enteric-coated Tablets in the treatment of peptic ulcer. Methods 84 cases of patients with peptic ulcer admitted to Jiangjin Central Hospital of Chongqing from April 2013 to December 2014 were selected and randomly divided into control group and observation group according to the order of hospitalization, with 42 cases in each group. Patients in control group were given triple therapy including Rabeprazole: Rabeprazole Sodium Enteric-coated Tablets orally, 20 mg per time, two times a day +Amoxicillin Capsules 0.5 g per time, three times a day +Metronidazole Tablets 0.4 g per time, three times a day. On basis of control group, observation group was given Kangfuxin Liquid orally, 10 mL once, three times a day. 4 weeks were as a course. The clinical symptom scores, clinical effect, gastroscope curative effect, Heli-cobacter pylori eradicating conditions, recurrent of peptic ulcer during half a year and adverse reactions between two groups were observed and compared. Results After a course of treatment, the six symptoms scores of stomachache, ab-dominal distension, pantothenic acid, heartburn, belching, nausea and vomiting and total scores of control group and observation group [control group: (1.56±0.49), (0.98±0.22), (1.05±0.24), (1.34±0.36), (0.92±0.14), (1.04±0.22), (5.84±1.92) points; observation group: (1.22±0.31), (0.86±0.17), (0.96±0.19), (1.27±0.34), (0.91±0.11), (1.06±0.27), (4.44±1.53) points] were all lower than those before treatment [control group: (4.27±1.41), (3.64±1.31), (4.63±1.93), (3.99±1.25), (3.61±0.98), (4.13±1.26), (22.14±5.16) points; observation group: (4.52±1.84), (3.85±1.21), (4.71±1.98), (4.01±1.29), (3.59±0.95), (4.25±1.39), (23.45±5.78) points], the differences were all statistically significant (P< 0.05). There were no statistically significant differences after treatment between two groups (P> 0.05). The clinical total effective <br> rate of observation group (95.24%) was higher than that of control group (88.10%), the difference was statistically sig-nificant (P< 0.05). The gastroscopic total effective rate of observation group reached to 100.00%, which was higher than that of control group (85.71%), the difference was highly statistically significant (P< 0.01). There was no statisti-cally significant difference of Helicobacter pylori eradicating rate between two groups (P> 0.05). The recurrent rate of peptic ulcer during half a year in observation group (21.43%) was lower than that in control group (33.33%), the differ-ence was statistically significant (P< 0.05). During the therapy, there were 3 cases of dry mouth in the control group, 2 cases of mild diarrhea and 1 case of dry mouth in observation group, they were all relieved by themselves after stop-ping drugs. Conclusion Kangfuxin Liquid combined with Rabeprazole Sodium Enteric-coated Tablets in the treatment of peptic ulcer has significant clinical effects, which can improve the clinical symptoms rapidly, prevent recurrence of ulcer, and the adverse reactions are slight, which is worthy of further clinical promotion and application.
